Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
759.33-
QQQ
703.391.61%
BTC/USD
77647.001.1031%
DIA
525.030.14%
GLD
395.450.83%
TLT
80.98-

Crescent Biopharma Inc

CBIONASDAQ
Trade with Public
Trade with Public
$19.41
-0.05-0.26%
At close: Sep 10, 5:00 PM EST
$19.41
-0.05-0.26%
Pre-Market: 4:13 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Crescent Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Crescent Biopharma (CBIO).

Price Target Range — 4 Quarters

Analyst Consensus — 6 Analysts

5Buy
1Hold
Consensus RatingBuy# Analysts6Avg. Consensus PT$28Upside to Avg. PT+42.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 27, 2026WedbushRobert DriscollMaintainedOutperform$27
Jun 1, 2026HC Wainwright & Co.Mitchell S. KapoorDowngradeBuy→Neutral—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
Benzinga Newsdesk

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.
Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Crescent Biopharma to Neutral

HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Crescent Biopharma (NASDAQ:CBIO) from Buy to Neutral.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and lowers the price target from $25 to $22.
Benzinga Newsdesk

This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

PRO
Guggenheim Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $35

Guggenheim analyst Brad Canino initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $35.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved